A Novel Pediatric Cancer Therapy Targeting Epigenetics and Neuroblastoma Differentiation
ISEF · 2018 Biomedical and Health Sciences Fourth Award
Overview
Neuroblastoma(NB) is a pediatric cancer present in children under the age of 16, responsible for a disproportionate 15% of all childhood cancer deaths worldwide. Traditionally cells differentiate from a stem cell into a mature cell; however, NB cells never reach full neuronal maturity and continue to proliferate in contrast to normal cells that reach maturity. Cis Retinoic Acid(CRA) is a treatment used today that induces differentiation in NB to improve patient treatment outcomes, though it causes harsh side effects and is thus not an optimal therapy for all patients. This study aimed to identify novel treatments for NB which have limited side effects for patients. Seven distinct inhibitors were investigated based on their proven ability to alter gene expression and protein regulation. Drug cytotoxicity assays were used to demonstrate anti-cancerous properties and identified Selinexor and DZNep, which are highly efficient inhibitors. To determine if differentiation was occurring, morphology and biochemical composition were examined. Microscopy identified changing morphological features of differentiation and immunofluorescence demonstrated changing protein concentrations related to neuronal differentiation. These revealed distinct differentiation properties similar to those induced by CRA. Western blot analysis further confirmed changing protein concentration related to neural differentiation patterns. In summary, this study confirmed the ability of epigenetic altering drugs to induce differentiation in NB cells in vitro and provided pre-clinical evidence of some essential, desirable properties of the drugs DZNep and Selinexor in the evaluation for new therapeutics for this disease. Both inhibitors demonstrate potential in improving treatment of NB patients.
Awards (2)
- Fourth Award of $500 $500
- Drug, Chemical & Associated Technologies Association (DCAT): First Award of $3,000. $3,000
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2026
Neuroblastoma and Glioblastoma Differentiation by Retinoic Acid: Epigenetic and Transcriptional Changes
ISEF · 2020
Survival Analysis of Pediatric Neuroblastoma Patients Using Gene Expression Data: Identification of Novel Neural Differentiation Related Biomarkers
ISEF · 2022
LncRNAs Influence on NK Cells: Potential Therapeutic Target for Neuroblastoma
ISEF · 2014
Nano-Formulated Quercetin: A Novel Therapy for Neuroblastoma by the Re-expression of RIZ1
ISEF · 2018
Development of Differentiation Therapies for NPM1 Mutated AML
ISEF · 2018
A Precision Medicine Approach to Cancer: Epigenetic Inhibitors Induce Highly-Specific Apoptosis in High Risk Acute Lymphoblastic Leukemia
ISEF · 2015
The Effect of Small Molecule Activators of PP2A (SMAPs) on N-Myc Driven Neuroblastomas
ISEF · 2023
Identifying the Molecular Mechanisms of a Safer Neuroblastoma Cure Using the Native Hawaiian 'Awapuhi (Zingiber zerumbet) Herb
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair